Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 million but is under legal investigation for fairness. Analyst Matthew Hewitt downgraded the stock to Hold with a $6.28 price target, reflecting the acquisition offer. Investors should watch the investigation outcome and potential CVR payouts for future gains.
Lifecore Biomedical's stock surge is noted alongside Pluang's health sector snapshot for context. For readers following health stocks, here is Pluang's market snapshot as of Sep 29, 2026 02:52 WIB: out of 100 priced health-sector US stocks, 52 rose and 47 fell. Among notable movers, Enveric Biosciences Inc (ENVB) declined 2.67% to USD 1.46 with a typical hold time of 13 days, Cytokinetics Inc (CYTK) rose 2.61% to USD 66.35 with a typical hold time of 19 days, and TransMedics Group Inc (TMDX) fell 2.56% to USD 83.11 with a typical hold time of 24 days and a Pluang order activity heavily skewed to selling at 97%.
A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...
Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stabl...
Conagra Brands is set to report Q1 earnings with analysts forecasting a 1.4% revenue decline to about $2.59 billion due to weak consumer spending and inflation. Earnings per share are expected to drop 20.5% to $0.31, reflecting margin pressures and a...
Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...
H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...
